JPH0118051B2 - - Google Patents
Info
- Publication number
- JPH0118051B2 JPH0118051B2 JP55042598A JP4259880A JPH0118051B2 JP H0118051 B2 JPH0118051 B2 JP H0118051B2 JP 55042598 A JP55042598 A JP 55042598A JP 4259880 A JP4259880 A JP 4259880A JP H0118051 B2 JPH0118051 B2 JP H0118051B2
- Authority
- JP
- Japan
- Prior art keywords
- sodium
- aqueous solution
- dissolution
- water
- observed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000011734 sodium Substances 0.000 claims description 36
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 20
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- DQDZQHMCPDUUPC-UHFFFAOYSA-N Sulfadimethoxine sodium Chemical compound [Na+].COC1=NC(OC)=CC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 DQDZQHMCPDUUPC-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229910021538 borax Inorganic materials 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 239000004328 sodium tetraborate Substances 0.000 claims description 3
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 3
- 229960000703 sulfadimethoxine sodium Drugs 0.000 claims description 3
- 235000010338 boric acid Nutrition 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- IZJAOWYNDLDRKM-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(6-methoxypyrimidin-4-yl)azanide Chemical compound [Na+].C1=NC(OC)=CC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 IZJAOWYNDLDRKM-UHFFFAOYSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 15
- 238000001556 precipitation Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000013078 crystal Substances 0.000 description 12
- 239000000654 additive Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013022 formulation composition Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229960000973 sulfadimethoxine Drugs 0.000 description 3
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001470497 Leucocytozoon Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- AENYAMPVQFAKHY-UHFFFAOYSA-N boric acid;potassium Chemical compound [K].OB(O)O AENYAMPVQFAKHY-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、水への溶解性がPHに極めて強く依存
するスルフアジメトキシンナトリウムまたはスル
フアモノメトキシンナトリウム（以下、各々
SD・NaまたはSM・Naと略す。）の水溶液の調
整に際し、添加剤として下記する添加剤から選ば
れる２種類以上を添加することを特徴とする
SD・NaまたはSM・Na水溶液の安定化方法に関
する。
従来、持続性サルフア剤として有用なSD・Na
及びSM・Naが動物薬例えば豚、鶏等のコクシ
ジウム症及びロイコチトゾーン病等の予防薬及び
治療薬として繁用されており、その投薬に際して
は多くの場合それらの原末か、または散剤を用
時、飲水に投薬濃度約500〜10000ppm程度に溶解
し投与されている。
しかしながら、SD・Na及びSM・Naは水への
溶解性がPHに強く依存し、PHの低い水へ溶解した
場合、溶解時、瞬時のうちに難溶性の遊離体であ
るスルフアジメトキシンまたはスルフアモノメト
キシン（以下、各々SD・ＨまたはSM・Ｈと略
す。）となり結晶を析出する。また、溶解時にお
いてSD・NaまたはSM・Naが完全に溶解してい
る場合でも、水溶液が塩基性となるために大気中
の炭酸ガス等を吸収し易く、水溶液のPHが経時的
に低下しSD・ＨまたはSM・Ｈの結晶が析出す
る。ところが、現在、日本各地の養豚場や養鶏場
では飲水として井戸水や河川の水を使用している
所が多く、場所によつては水のPHが異常に低い場
合がある。したがつて大量のSD・ＨまたはSM・
Ｈが容易に結晶として析出し、送水系のパイプが
詰るなどして薬剤の投与及び飲水の送水に支障を
きたすことがしばしば見られ、改善策が種々検討
されている。
そこで、本発明者等は、SD・Na及びSM・Na
の溶解性が、溶解時及び溶解後ともに溶解する水
または水溶液の液性（PH）に影響されない、即ち
SD・ＨまたはSM・Ｈの結晶を析出することのな
い安定な水溶液を調製すべく添加剤及び製剤組成
物等について種々検討した。その結果、添加剤と
して下記する成分群より特定の２種類以上を選
択、添加することにより、SD・Na及びSM・Na
の溶解時の溶解性を高め、溶解時及び溶解後とも
に結晶を析出しない安定な溶液系とすることがで
きうることを見い出し本発明を完成した。
本発明の有効成分であるSD・NaまたはSM・
Naの含有量は目的とする水溶液の濃度に応じて
調整することができる。
本発明の添加剤としては、例えば炭酸ナトリウ
ム、炭酸水素ナトリウム、ホウ酸、ホウ砂、塩化
カリウム等が挙げられ、使用に際しては前記群よ
り特定の２種類以上の成分を適宜選択し添加すれ
ばよい。好ましい添加剤の組み合せとしては、例
えば炭酸水素ナトリウム―乾燥炭酸ナトリウム、
ホウ砂−乾燥炭酸ナトリウム、ホウ酸―塩化カリ
ウム―乾燥炭酸ナトリウム等が挙げられる。
また、添加剤の総添加量は主薬含有量に対し、
0.02〜19倍重量に調整することができる。但し、
添加剤間の重量比は溶解後、PH約９〜11の範囲と
なるように調整するのが好ましい。
前記添加物を使用して、安定なSD・Naまたは
SM・Naの水溶液を調製するに際しては、用時、
SD・NaまたはSM・Naと選択した特定の添加剤
とを各々単独に水及び水溶液へ添加溶解するか、
または予め前記両者を含有する製剤組成物とし、
用時単に溶解すればよい。また必要に応じて撹拌
溶解するのが好ましい。
上記SD・NaまたはSM・Naの製剤組成物を調
製するに際しては、主薬のSD・NaまたはSM・
Naと選択した特定の添加剤とを各々粉末状態で
均一に混合し、必要に応じて散剤、顆粒剤、錠剤
の製剤とすればよい。
また、前記水溶液の調製及び製剤組成物の製剤
化に際しては、適宜、通常製剤加工に使用される
保存剤、流動化剤、賦形剤等を添加することがで
きる。
本発明の方法を使用すれば、溶解時の主薬の溶
解度を高め、且つ経時的にも大気中において安定
でSD・Ｈ及びSM・Ｈの結晶を析出しない、ひい
ては養豚場及び養鶏場における結晶析出にともな
う投薬濃度の低下あるいは送水系パイプの詰など
による投薬及び送水の支障を防止しうる安定な
SD・NaまたはSM・Naの水溶液を調製すること
ができる。
以下、本発明を実施例を挙げて詳細に説明す
る。
実施例 １
スルフアジメトキシンナトリウム（SD・Na）
50ｇ、炭酸水素ナトリウム45ｇ及び乾燥炭酸ナト
リウム５ｇを混合して散剤100ｇを調製し、この
製剤組成物２ｇをPH２〜８（HCl〜NaOHにて調
製）の水溶液100mlに溶解し、SD・Na水溶液を
調製した。その結果、溶解時にスルフアジメトキ
シン（＝SD・Ｈ）の析出は認められず、また溶
解後、数日経過後も溶液のPHは低下せず、また
SD・Ｈの析出も認められなかつた。
尚、同時に100ｇ中SD・Na50ｇ及び乳糖50ｇ
の組成を有する通常の製剤についても同様に検討
した結果、溶解後２日目でPHが低下し、SD・Ｈ
の析出が認められた。
以下、実験結果を表１に示す。
The present invention uses sulfadimethoxine sodium or sulfamomonomethoxine sodium (hereinafter referred to as
Abbreviated as SD・Na or SM・Na. ) is characterized in that two or more types selected from the following additives are added as additives when preparing the aqueous solution of
Concerning a method for stabilizing SD/Na or SM/Na aqueous solutions. Previously, SD/Na was useful as a long-acting sulfur drug.
SM and Na are frequently used as preventive and therapeutic agents for coccidiosis and leucocytozoon disease in animals such as pigs and chickens, and their bulk powder or powder is often used when administering them. When used, it is dissolved in drinking water to a concentration of approximately 500 to 10,000 ppm and administered. However, the solubility of SD・Na and SM・Na in water strongly depends on the pH, and when dissolved in water with a low pH, the poorly soluble free form sulfadimethoxine or sulfadimethoxine or It becomes monomethoxine (hereinafter abbreviated as SD・H or SM・H, respectively) and precipitates crystals. In addition, even if SD/Na or SM/Na is completely dissolved at the time of dissolution, the aqueous solution becomes basic and easily absorbs carbon dioxide, etc. in the atmosphere, and the pH of the aqueous solution decreases over time. Crystals of SD・H or SM・H precipitate. However, many pig farms and poultry farms across Japan currently use well water or river water for drinking water, and depending on the location, the pH of the water may be abnormally low. Therefore, a large amount of SD・H or SM・
It is often observed that H easily precipitates as crystals, clogging the pipes of the water supply system, thereby interfering with the administration of medicines and the supply of drinking water, and various remedies are being considered. Therefore, the present inventors investigated SD・Na and SM・Na.
The solubility of the compound is not affected by the pH of the water or aqueous solution in which it is dissolved both during and after dissolution, i.e.
In order to prepare a stable aqueous solution of SD/H or SM/H that does not precipitate crystals, various additives and formulation compositions were investigated. As a result, by selecting and adding two or more specific additives from the component groups listed below, SD・Na and SM・Na
The present invention was completed based on the discovery that it is possible to improve the solubility during dissolution and to create a stable solution system in which crystals do not precipitate both during and after dissolution. SD/Na or SM/ which is the active ingredient of the present invention
The Na content can be adjusted depending on the target concentration of the aqueous solution. Examples of the additives of the present invention include sodium carbonate, sodium hydrogen carbonate, boric acid, borax, potassium chloride, etc. When used, two or more specific components from the above groups may be appropriately selected and added. . Preferred additive combinations include, for example, sodium bicarbonate-dry sodium carbonate;
Examples include borax-dry sodium carbonate, boric acid-potassium chloride-dry sodium carbonate, and the like. In addition, the total amount of additives added is relative to the active ingredient content.
Can be adjusted from 0.02 to 19 times the weight. however,
The weight ratio between the additives is preferably adjusted so that the pH ranges from about 9 to 11 after dissolution. Using the above additives, stable SD・Na or
When preparing an aqueous solution of SM/Na, at the time of use,
Add and dissolve SD/Na or SM/Na and selected specific additives into water or an aqueous solution, or
Or a pharmaceutical composition containing both of the above in advance,
It can be simply dissolved before use. Further, it is preferable to stir and dissolve as necessary. When preparing the above SD/Na or SM/Na formulation, the main drug SD/Na or SM/Na should be prepared.
Na and the selected specific additives may be uniformly mixed in powder form to prepare powders, granules, or tablets as required. Furthermore, when preparing the aqueous solution and formulating the pharmaceutical composition, preservatives, fluidizing agents, excipients, etc. that are commonly used in pharmaceutical processing can be added as appropriate. If the method of the present invention is used, the solubility of the main drug during dissolution will be increased, and it will be stable in the atmosphere over time and will not precipitate SD/H and SM/H crystals, thereby preventing crystal precipitation in pig farms and poultry farms. A stable solution that can prevent problems with medication and water supply due to decreases in medication concentration or clogging of water supply pipes.
Aqueous solutions of SD.Na or SM.Na can be prepared. Hereinafter, the present invention will be explained in detail by giving examples. Example 1 Sulfadimethoxine sodium (SD・Na)
50 g of sodium bicarbonate, 45 g of dry sodium carbonate, and 5 g of dry sodium carbonate were mixed to prepare 100 g of powder, and 2 g of this formulation composition was dissolved in 100 ml of an aqueous solution with a pH of 2 to 8 (prepared with HCl to NaOH). Prepared. As a result, no precipitation of sulfadimethoxine (=SD・H) was observed during dissolution, and the pH of the solution did not decrease even after several days after dissolution.
No precipitation of SD/H was observed. At the same time, 50g of SD/Na and 50g of lactose in 100g
A similar study was conducted on a conventional formulation with the following composition: PH decreased on the second day after dissolution, and SD/H
Precipitation was observed. The experimental results are shown in Table 1 below.
【表】
＋：結晶析出有り
−： 〃 無し
実施例 ２
SD・Na50ｇ、ホウ砂40ｇ及び乾燥炭酸ナトリ
ウム10ｇを混合し、散剤100ｇを調製し、その製
剤組成物２ｇを水（PH５〜６）100mlに溶解し、
SD・Na水溶液を調製した。その結果、溶解時に
SD・Ｈの析出は認められず、また溶解後も経時
的なPHの低下は認められなかつた。尚、実施例１
に記した通常の製剤の水への溶解性についても同
時検討した結果、経時的にPHが低下し、SD・Ｈ
の析出が認められた。
以下、本実験の結果を表２に示す。[Table] +: Crystal precipitation -: None Example 2 50 g of SD Na, 40 g of borax and 10 g of dry sodium carbonate were mixed to prepare 100 g of powder, and 2 g of the formulation was added to 100 ml of water (PH5-6). dissolved in
An aqueous SD/Na solution was prepared. As a result, upon dissolution
No precipitation of SD/H was observed, and no decrease in pH over time was observed even after dissolution. Furthermore, Example 1
As a result of simultaneously examining the water solubility of the ordinary formulation described in 2.2, the PH decreased over time, and the SD/H
Precipitation was observed. The results of this experiment are shown in Table 2 below.
【表】
＋：結晶析出有り
−： 〃 無し
実施例 ３
SD・Na50ｇ、ホウ酸15ｇ、塩化カリウム10ｇ
及び乾燥炭酸ナトリウム25ｇを混合し散剤100ｇ
を調製し、この製剤組成物２ｇを水100mlに溶解
しSD・Na水溶液を調製した。その結果、溶解時
にSD・Ｈの析出は認められず、また、溶解後も
経時的なPHの低下及びSD・Ｈの析出は認められ
なかつた。
以下、本実験結果を表３に示す。[Table] +: Crystal precipitation -: None Example 3 SD・Na 50g, boric acid 15g, potassium chloride 10g
and 25g of dry sodium carbonate to make 100g of powder.
2 g of this pharmaceutical composition was dissolved in 100 ml of water to prepare an SD/Na aqueous solution. As a result, no precipitation of SD/H was observed during dissolution, and no decrease in pH or precipitation of SD/H over time was observed even after dissolution. The results of this experiment are shown in Table 3 below.
【表】
−：結晶析出無し
実施例 ４
SD・Na96ｇ、炭酸水素ナトリウム２ｇ及び乾
燥炭酸ナトリウム２ｇを混合し、散剤100ｇを調
製し、その製剤組成物１ｇを水100mlに溶解し、
SD―Na水溶液を調製した。その結果、溶解時に
SD・Ｈの析出は認められなかつた。また、溶解
後は経時的に若干のPHの低下が認められたが、
SD・Ｈの結晶析出は認められなかつた。
以下、本実験結果を表４に示す。[Table] -: No crystal precipitation Example 4 96 g of SD Na, 2 g of sodium bicarbonate and 2 g of dry sodium carbonate were mixed to prepare 100 g of powder, and 1 g of the formulation composition was dissolved in 100 ml of water.
An aqueous SD-Na solution was prepared. As a result, upon dissolution
No precipitation of SD/H was observed. In addition, a slight decrease in pH was observed over time after dissolution, but
No crystal precipitation of SD/H was observed. The results of this experiment are shown in Table 4 below.
【表】
−：結晶析出無し
[Table] −: No crystal precipitation
Claims (1)
フアモノメトキシンナトリウムを有効成分とする
水溶液の調整に際し、炭酸ナトリウム、炭酸水素
ナトリウム、ホウ酸、ホウ砂及び塩化カリウムか
らなる群より選択した二種類以上を添加すること
を特徴とするスルフアジメトキシンナトリウムま
たはスルフアモノメトキシンナトリウム水溶液の
安定化方法。1. When preparing an aqueous solution containing sodium sulfadimethoxine or sodium sulfamonomethoxine as an active ingredient, two or more selected from the group consisting of sodium carbonate, sodium hydrogen carbonate, boric acid, borax, and potassium chloride are added. A method for stabilizing an aqueous solution of sulfadimethoxine sodium or sulfamomonomethoxine sodium, characterized by:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4259880A JPS56139414A (en) | 1980-04-01 | 1980-04-01 | Stabilizing method of aqueous solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4259880A JPS56139414A (en) | 1980-04-01 | 1980-04-01 | Stabilizing method of aqueous solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56139414A JPS56139414A (en) | 1981-10-30 |
| JPH0118051B2 true JPH0118051B2 (en) | 1989-04-03 |
Family
ID=12640486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4259880A Granted JPS56139414A (en) | 1980-04-01 | 1980-04-01 | Stabilizing method of aqueous solution |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56139414A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950010150B1 (en) * | 1986-01-14 | 1995-09-11 | 쥬우가이세이야꾸 가부시끼가이샤 | Method of the stabilization of nicorandil injection |
| JPS6396126A (en) * | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | Stabilized composition |
| JPS63159317A (en) * | 1986-12-24 | 1988-07-02 | Terumo Corp | Allantoin-containing aqueous preparation |
| CN1054127C (en) * | 1996-07-16 | 2000-07-05 | 中国医药研究开发中心 | Process for preparing monohydrate of sulfamonomethoxine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4918670A (en) * | 1972-06-14 | 1974-02-19 |
-
1980
- 1980-04-01 JP JP4259880A patent/JPS56139414A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4918670A (en) * | 1972-06-14 | 1974-02-19 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56139414A (en) | 1981-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2735903B2 (en) | Ibuprofen boiling formulation | |
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| EP0011489B1 (en) | An analgesic effervescent powder and process for its preparation | |
| JP4804431B2 (en) | Long acting oxytetracycline composition | |
| UA72541C2 (en) | A pharmaceutical composition containing benzamide derivative | |
| JPS584720A (en) | Analgesic medicinal composition | |
| JPH0347161A (en) | Stable liquid from of 5-aminosalicyclic acid | |
| JP2893140B2 (en) | Stable vitamin D preparation | |
| US20080233196A1 (en) | Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles | |
| EP0154009A1 (en) | Use of a thiazide diuretic for the manufacture of a non-diuretic antihypertensive medicament | |
| SI21259A (en) | Pharmaceutical compositions with antibiotic activity | |
| US3621094A (en) | Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts | |
| JPH0118051B2 (en) | ||
| US4128632A (en) | Solubilization of Rafoxanide | |
| JPS605567B2 (en) | Oxytetracycline preparation | |
| US4428951A (en) | Long acting pharmaceutical composition | |
| EP0159777A1 (en) | Stabilized 4-carbamoyl-imidazolium-5-olate | |
| RU2527042C1 (en) | Biologically active food additive for osteoporosis prevention | |
| JP2594395B2 (en) | Stabilization method and formulation of sodium azulene sulfonate | |
| JPS62126130A (en) | Medicinal composition for animals | |
| CA1154676A (en) | Ready for use, injectable, aqueous solutions of alkali metal salts of canrenoic acid and furosemide and process for their preparation | |
| US3592890A (en) | Method of combating atrophic rhinitis | |
| US3655882A (en) | Stable dietary supplement for new born pigs | |
| JP2002284679A (en) | Stable solid preparation composition containing thyroid hormone | |
| JPS60260510A (en) | Injection solution for ketonemia |